ArticleiScience2025
Prognostic impact of CRAFITY score in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of hepatocellular carcinoma (HCC), yet identifying patients most likely to benefit remains challenging. We evaluated the prognostic significance of the C-reactive protein and alpha-fetoprotein in immunotherapy (CRAFITY) score, a composite index integrating C-reactive protein and alpha-fetoprotein, in HCC treated with ICIs. A systematic review and meta-analysis of 17 studies comprising 3,730 patients demonstrated that higher baseline CRAFITY scores were consistently associated with shorter overall and progression-free survival, as well as lower response and disease control rates. Complementing these findings, a retrospective analysis of 129 ICI-treated patients at our institution confirmed that elevated CRAFITY scores predicted significantly poorer survival outcomes. These results highlight the CRAFITY score as a simple, readily available biomarker that captures systemic inflammation and tumor burden, enabling more precise prognostic stratification and potentially guiding therapeutic decision-making in patients receiving immunotherapy for advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.